Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Infosys Limited (INFY) vs Smith & Nephew plc (SNN) Price & Performance

Infosys LimitedTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Infosys Limited vs Smith & Nephew plc — how do they compare? Infosys Limited trades at $12.36 (market cap $50.55B), while Smith & Nephew plc trades at $29.95 (market cap $12.54B). The key difference: Infosys Limited is far larger — about 4× Smith & Nephew plc's market cap, and Infosys Limited pays the higher dividend (4.16%). Which is the better fit depends on your goals.

INFYSNN
Market Cap
$50.55B$12.54B
Sector
TechnologyHealth
52-Week High
$20.22$38.70
52-Week Low
$10.49$28.73
Enterprise Value
$48.30B$15.57B
Dividend Yield
4.16%2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Infosys Limited

No Aura AI signal available yet.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.

Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.

Returns comparison

Trailing returns across standard periods

About Infosys Limited

Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.

Read more on INFY

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN